Kathrine Morin

Katie Morin focuses her practice on corporate law and public finance law.

Katie’s public finance experience encompasses a wide variety of matters relating to the issuance of tax-exempt and taxable bonds, including representation of issuers and borrowers in connection with general obligation and revenue bond transactions. She has served as bond counsel to various cities, towns and quasi-public agencies.

Katie’s public finance experience includes drafting primary financing documents, including loan and trust agreements, official statements, purchase agreements, legislation, opinions and various closing certificates.

Katie’s corporate law practice is focused on assisting private equity firms and their portfolio clients in connection with a variety of transactional needs. She also has experience assisting public and private companies with a variety of general corporate matters.

Katie has been involved in the following transactions:

• Greenbacker Capital Management in its investment in Sunrock Distributed Generation
• Led the representation of Oscor, Inc., in its sale of $220 million to Integer Holdings Corporation
• Represented American Tower Corporation in the acquisition of data centers located in Orlando and Atlanta operated by DataSite
• Represented Silver Oak Services Partners, LLC, in the recapitalization of Drive Automotive Services, LLC
• Led the representation of Enhanced Energy Group, Inc., operating as CarbonPoint Solutions, in its sale to Caterpillar Inc.
• Assisted in the representation of Shanghai Haohai Biological Technology Co., Ltd., in connection with its $40 million Series A preferred equity investment in Eirion Therapeutics, Inc., and related licensing agreements
• Assisted in the representation of Silver Oak Services Partners, LLC, in its sale of BBG, Inc., to Incline Equity Partners
• Assisted in the representation of KPS Mid-Cap Investments, an affiliate of KPS Capital Partners, in the acquisition of Libertas Copper LLC
• Assisted in the representation of Biohaven Pharmaceutical Holding Company in its acquisition of the remaining 58% interest of Kleo Pharmaceuticals, Inc., that it did not previously own and the execution of an exclusive license agreement with Yale University for a novel extracellular degrader technology licensed from the Spiegel Lab
• Assisted in the representation of the Seller of Falk Marques Group to Pageant Media US Limited
• Led the representation of Biohaven Pharmaceutical Holding Company and its affiliate BioShin Limited in a $60 million Series A preferred equity financing of BioShin Limited, BioShin’s subsidiary